Management of patients with advanced non-small cell lung cancer: Current and emerging options

Drugs

Volumn 70, Issue 2, 2010, Pages 167-179

  Triano, Laura R ^a   Deshpande, Hari ^a   Gettinger, Scott N ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Bevacizumab, therapeutic use; Cetuximab, therapeutic use; Erlotinib; Non small cell lung cancer; Therapeutic use; Treatment

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANAPLASTIC LYMPHOMA KINASE; BELAGENPUMATUCEL L; BEVACIZUMAB; BIBF 1120; CANCER VACCINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CP 751871; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB; TALACTOFERRIN ALPHA; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FOOD AND DRUG ADMINISTRATION; HEMOPTYSIS; HUMAN; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PAIN; QUALITY OF LIFE; RASH; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; SALVAGE THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 75749145931     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11532200-000000000-00000     Document Type: Review

References (84)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24 (14): 2137-2150
2. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda (MD): National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/csr/1975-2005/[Accessed 2009 Apr 1]
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714 (Pubitemid 47357522)
4. Non-small Cell Lung Cancer Collaborative Group. Chemo-therapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899
5. Non-small Cell Lung Cancer Collaborative Group. Chemo-therapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26 (28): 4617
6. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16 (7): 2459-2465
7. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18 (1): 122-130
8. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B (Study 9730). J Clin Oncol 2005; 23 (1): 190-196
9. Groen H, Schramel FM, van der Hoeven JJM, et al. Docetaxel and carboplatin once every three weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC): an interim analysis of a multicenter phase III trial [abstract]. Proc Am Soc Clin Oncol 2003; 22: 623
10. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemci-tabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23 (33): 8380-8388
11. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99 (11): 847-857
12. Ardizzoni A. CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) [abstract no. 7011 plus oral presentation]. Lung cancer I. 2006 ASCO Annual Meeting; 2006 Jun 2-6; Atlanta (GA) [online]. Available from URL: http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm- session-presentations-view&confID=40&sessionID =369 [Accessed 2010 Jan 22]
13. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024
14. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98
15. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pe-metrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550 (Pubitemid 44917502)
17. Johnson DH, Fehrenbacher L, Novotny WF, et al. Random-ized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191
18. Polikoff J, Hainsworth JD, Fehrenbacher L, et al. Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS [abstract]. J Clin Oncol 2008; 26: 8079
19. Akerley WL, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer [abstract]. J Clin Oncol 2008; 26: 8043
20. Lynch TJ, Brahmer J, Fischbach N, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract]. J Clin Oncol 2008; 26: 8077
21. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27 (8): 1227-1234
22. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531
23. Lynch TJ, Patel T, Dreisbach L, et al. Overall survival results from the phase III trial BMS 099: cetux-imab+taxane/carboplatin as 1st-line treatment for advanced NSCLC [abstract]. J Thorac Oncol 2008; 2: S305
24. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22 (5): 777-784 (Pubitemid 41103588)
25. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22 (5): 785-794 (Pubitemid 41103589)
26. Herbst RS, Prager D, Hermann R, et al., on behalf of the TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23 (25): 5892-5899
27. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cis-platin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2004; 23: 617
28. Hospital Arnau de Vilanova. Erlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of one chemotherapy regimen [ClinicalTrials.gov identifier NCT00908336]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00908336?term=NCT00908336& rank=1 [Accessed 2009 Dec 24]
29. Dutch Society of Physicians for Pulmonology and Tubercu-losis. 2nd line erlotinib treatment with (out) chemotherapy of advanced non small cell lung cancer (NSCLC) (NVALT10) [ClinicalTrials.gov identifier NCT00835471]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00835471?term=NCT00835471&rank=1 [Accessed 2009 Dec 24]
30. National Cancer Institute (NCI). Docetaxel, cisplatin, pegfilgrastim, and erlotinib in treating patients with stage IIIB or stage IV non-small cell lung cancer [ClinicalTrials. gov identifier NCT00723138]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials. gov/ct2/show/NCT00723138?term=NCT00723138&rank=1 [Accessed 2009 Dec 24]
31. Hoffmann-La Roche. A study of tarceva (erlotinib) orplacebo in combination with platinum-based therapy as first line treatment in patients with advanced or recurrent non-small cell lung cancer [ClinicalTrials.gov identifier NCT00883779]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00883779?term= NCT00883779&rank=11 [Accessed 2009 Dec 24]
32. National Cancer Institute (NCI). Pemetrexed disodium with or withouteErlotinib in treating patients with stage IIIB or stage IV non-small cell lung cancer that responded to previous erlotinib [ClinicalTrials.gov identifier NCT00660816]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00660816? term=NCT00660816&rank=1 [Accessed 2009 Dec 24]
33. National Cancer Institute (NCI). Paclitaxel, carboplatin, and gefitinib in treating patients with advanced non-small cell lung cancer [ClinicalTrials.gov identifier NCT00660816]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/ show/NCT01024712?term=NCT01024712.&rank=1 [Accessed 2009 Dec 24]
34. Riely G, Rizvi N, Kris M, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 264-270
35. Shepherd FA, Dancey J, Ramlau R, et al. Prospective ran-domized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10): 2095-2103
36. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22 (9): 1589-1597
37. Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328. 12th World Conference on Lung Cancer; 2007 Sep 2-6; Seoul. J Thorac Oncol 2007 Aug; 2 (8 Suppl.): 851S
38. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al., on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2): 123-132
39. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366 (9496): 1527-1537
40. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21 (12): 2237-2246
41. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; (16): 2149-2158
42. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-1818
43. Scagliotti G, von Pawel J, Reck M. Sorafenib plus carbo-platin/paclitaxel in chemonaive patients with stage IIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled ESCAPE (Evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial [abstract]. J Thorac Oncol 2008; 3 (4) Suppl. 1: 275O
44. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adeno-carcinomas. J Clin Oncol 2006; 24 (11): 1700-1704
45. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95 (8): 998-1004
46. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006; 95 (11): 1483-1489
47. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24 (21): 3340-3346
48. Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II pro-spective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007; 56 (3): 383-389
49. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A pro-spective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) [abstract]. J Clin Oncol 2006; 24: 7020
50. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26 (15): 2442-2449
51. Tamura K, Okamoto I, Kashii T, et al. Multicentre pro-spective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008; 98 (5): 907-914
52. Mok T, Wu Y, Thongprasert S, et al. Gefitinib or carbo-platin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
53. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group [abstract]. J Clin Oncol 2009; 27: 8016
54. Zhu C, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275
55. Hirsch F, Varella-Garcia M, Bunn P, et al. Molecular pre-dictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042
56. Fukuoka M, Wu Y, Thongprasert S, et al. Biomarker ana-lyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS) [abstract]. J Clin Oncol (Meeting Abstracts) 2009; 27: 8006
57. Adjei A, Edelman M, Carbone D, et al. Phase III rando-mized study of pemetrexed disodium versus erlotinib hydrochloride as second-line therapy in patients with advanced non-small cell lung cancer [online]. Available from URL: http://www.cancer.gov/clinicaltrials/NCCTG-N0723 [Accessed 2009 May 1]
58. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26 (20): 3351-3357
59. Dziadziuszko R, Holm B, Skov BG, et al. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 2007; 18: 447-452
60. Hirsch FR, Varella-Garcia M, Bunn Jr PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807
61. O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study [abstract]. J Clin Oncol 2009; 27: 8007
62. Khambata-Ford S, Harbison C, Woytowitz D, et al. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial [abstract]. J Clin Oncol 2009; 27: 8021
63. National Cancer Institute (NCI). Carboplatin and paclitaxel with or without bevacizumab and/or cetuximab in treating patients with stage IV or recurrent non-small cell lung cancer [ClinicalTrials.gov identifier NCT00660816]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00660816?term= NCT00660816&rank=1 [Accessed 2009 Dec 24]
64. Reily GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6 (2): 201-205
65. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mu-tation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896
66. Brugger W, Triller N, Blasinska-Morawiec M, et al. Bio-marker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC [abstract]. J Clin Oncol 2009; 27: 8020
67. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colo-rectal cancer. N Engl J Med 2008; 359 (17): 1757-1765
68. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 ex-pression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8 (7): 2286-2291
69. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355 (10): 983-991
70. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small cell lung cancer. J Clin Oncol 2007; 25 (19): 2747-2754
71. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64 (11): 3761-3766
72. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24 (29): 4731-4737
73. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 2741-2746
74. Bepler G. Phase III of RRM1 & ERCC1 directed customized chemotherapy for the treatment of patients with NSCLC [online]. Available from URL: http//clinicaltrials.gov/ct2/show/NCT00499109?term=bepler&rank=1 [Accessed 2009 May 1]
75. Iwahara T, Fujimoto J, Wen D, et al. Molecular character-ization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439-449
76. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1287
77. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566
78. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring EML4-ALK. J Clin Oncol 2009; 27: 4247-4253
79. Shaw AT, Costa DB, Iafrate AJ, et al. Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK transloca-tions [abstract]. J Thorac Oncol 2009; 4 Suppl. 1: S305 (A6.4)
80. Pfizer. An investigational drug, PF-02341066 is being stu-died versus standard of care in patients with advanced non-small cell lung cancer with a specific gene profile involving the anaplastic lymphoma kinase (ALK) gene [ClinicalTrials. gov identifier NCT00660816]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/ show/NCT00932893?term=NCT00932893&rank=1 [Accessed 2009 Dec 24]
81. Ciuleanu T, T Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374 (9699): 1432-1440
82. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carci-noma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107 (7): 1589-1596
83. Sigmond J, Backus HHJ, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66 (3): 431-8 84.
84. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68 (1): 110-118 (Pubitemid 41002949)